All In Biotech

Drug Trial Radar · NCT07690826

A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Participants With Obesity

Last checked: Nov 20, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 252 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

252

Planned (sponsor's estimate)

Start

Jul 2026

Primary completion

Mar 2027

Study completion Jul 2027

Sponsor

Sponsor type
Industry
First posted
Jul 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy and safety of once-weekly HRS-4729 injection in adults with obesity without diabetes. Approximately 252 participants will be enrolled. The primary endpoint is percent change in body weight from baseline at Week 32 versus placebo.

Conditions

  • Overweight or Obesity

Interventions

  • HRS-4729 InjectionDrug

    HRS-4729 Injection; Dose 1

  • HRS-4729 InjectionDrug

    HRS-4729 Injection; Dose 2

  • HRS-4729 InjectionDrug

    HRS-4729 Injection; Dose 3

  • HRS-4729 Injection;Drug

    HRS-4729 Injection; Dose 4

  • HRS-4729 Injection;Drug

    HRS-4729 Injection; Dose 5

  • HRS-4729 Injection;Drug

    HRS-4729 Injection; Dose 6

  • HRS-4729 Injection PlaceboDrug

    HRS-4729 Injection Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Body WeightTime frame: Baseline, Week 32

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.